Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms

Get unlimited access to all IAM content